Clinical value of modern premix insulin: Convenience in quality and safety

Abstract

Guidelines for people with type 2 diabetes who have failed to maintain glycemic control with oral antidiabetic treatments recommend additional treatment options, including starting incretins followed by initiating insulin treatment (with either a basal insulin or a premixed insulin regimen). Within 1 year, most patients on basal analogue insulin will also need to add mealtime insulin to reach HbA1c target. International guidelines endorse premix insulin for initiation. The recent consensus report by ADA stated that If HbA1c remains above target; add prandial insulin usually one dose with the largest meal or meal with greatest PPG excursion; prandial insulin can be dosed individually. Also, it recommends that to consider initiation of a self-mixed or premixed insulin regimen to decrease the number of injections required. BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy for type 2 diabetes. Adding BIAsp30 once daily or twice daily improves glycemic control more effectively than optimizing OAD therapy by targeting both PPG and FPG, unlike basal insulin. BIAsp 30 has a similar pharmacokinetic profile to biphasic insulin lispro 25, but with a significantly lower postprandial glucose excursion. Moreover, it provides effective glycemic control, lowers risk of major or nocturnal hypoglycaemia and simpler intensification while switching from other regimens.

Keywords: Premix insulin, BIAsp 30, Prandial insulin